Akums Drugs & Pharmaceuticals Ltd's Q4FY25 Quarterly Results

Result Summary

• Akums Drugs & Pharmaceuticals Ltd reported a 6.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were up by 5.2% QoQ and - - YoY.
• The net profit decreased 159.5% QoQ and - - YoY.
• The earnings per share (EPS) of Akums Drugs & Pharmaceuticals Ltd declined at 2.9 during Q4FY25.

Financial Statments for Q4FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Akums Drugs & Pharmaceuticals Ltd is a prominent name in the Indian pharmaceutical industry, primarily engaged in the manufacturing of pharmaceutical formulations. The company is known for its expertise in providing contract manufacturing services to various pharmaceutical companies. Akums' product portfolio includes a wide range of pharmaceutical formulations such as tablets, capsules, injections, and other medicinal products. The company has established itself as a trusted partner for quality manufacturing in the pharmaceutical sector. Currently, there is no additional information provided about any recent major developments or changes within the company.

Revenue

In the fourth quarter of the financial year 2025 (Q4FY25), Akums Drugs & Pharmaceuticals Ltd reported a total income of ₹954.45 crores. This represents a quarter-over-quarter (QoQ) decrease of 6.9% from the third quarter of the same financial year (Q3FY25), where the total income was ₹1024.97 crores. The financial data does not provide a year-over-year (YoY) comparison for Q4FY24, as the income for Q4FY24 is recorded as ₹0.00 crores. This lack of historical data implies that making a year-over-year comparison or drawing insights from it is not feasible based on the available information.

Profitability

The profitability metrics for Akums Drugs & Pharmaceuticals Ltd in Q4FY25 indicate a challenging quarter. The company reported a loss before tax of ₹32.88 crores, a significant decline from a profit of ₹91.05 crores in Q3FY25. This reflects a QoQ decrease of 136.1%. The tax expense for Q4FY25 was ₹6.58 crores, compared to ₹24.74 crores in Q3FY25, showing a decrease of 73.4%. Consequently, the profit after tax for Q4FY25 was a negative ₹39.47 crores, in stark contrast to a positive ₹66.31 crores in Q3FY25, marking a QoQ change of -159.5%. The earnings per share (EPS) for Q4FY25 stood at ₹-2.90, compared to ₹4.30 in Q3FY25, with a QoQ change of -167.4%. The data for Q4FY24 is not available for profitability comparison.

Operating Metrics

The total expenses for Akums Drugs & Pharmaceuticals Ltd in Q4FY25 were reported at ₹987.55 crores, up 5.2% from ₹938.70 crores in Q3FY25. This increase in expenses, coupled with the decline in total income, contributed to the negative profitability for the quarter. Unfortunately, due to the absence of specific figures from the previous year, a year-over-year analysis for operating metrics is not possible. The financial data provided does not include additional operating metrics such as production volume or cost per unit, which limits further insights into the operational efficiency of the company during this period.